I updated this to reflect some extra detail that is now available. The clinical trial covered 309 patients at 21 institutions. The 5 year progression-free survival was:
• low risk- 97%
• favorable intermediate risk- 100%
• unfavorable intermediate risk - 93%
These excellent results were achieved without adding hormone therapy and are similar to results achieved for conventional IMRT with hormone therapy.
There were very low rates of late-term serious side effects (0% rectal, 1% urinary).
There are ongoing clinical trials for SBRT use with high risk prostate cancer.